Motivation to succeed, mission to reduce disability
BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders. Led by a passionate management team augmented by 20 years of pioneering research, the company has identified and is developing a pipeline of drugs focused on nerve repair and regeneration.
The company’s lead program licensed to Vertex Pharmaceuticals is actively recruiting in a Phase 2b/3 clinical trial to treat acute spinal cord injury. The SPRING SCI clinical trial is explained here.